#Belgium #Leuven #P95 BV #LatinaBA #vaccine research

P95 and LatinaBA Join Forces to Propel Vaccine Research

P95 BV, a prominent full-service Contact Research Organization (CRO) well-regarded for its focus on vaccine development and infectious diseases, has announced a significant strategic partnership with LatinaBA. This collaboration aims to enhance the landscape of vaccine and infectious disease research across Latin America.

Strengthening Clinical Research

With over 15 years of experience in conducting clinical trials throughout the region, LatinaBA brings invaluable expertise and local knowledge that complements P95's strengths. Together, the two organizations will merge their resources and capabilities to boost the efficacy and reach of clinical and epidemiological trials. The partnership marks a pivotal moment in the ongoing efforts to combat infectious diseases and enhance public health in Latin America.

Enhanced Collaborative Approach

Thomas Verstraeten, CEO of P95, expressed enthusiasm about the new alliance, highlighting the benefits of LatinaBA's deep understanding of the regional research needs. He stated, “This partnership represents a significant step forward, allowing us to unite our efforts to serve vaccine manufacturers and healthcare providers more effectively.”

On the other hand, Mariano Zarzecki, CEO of LatinaBA, emphasized the potential impact of the collaboration: “By combining our expertise, we can improve treatment options available to patients and extend our clients' opportunities in the evolving vaccine market.”

Comprehensive Services for All Research Phases

The collaboration will focus on providing tailored services across all phases of clinical research. By extending their operations to accommodate additional countries in Latin America, P95 and LatinaBA aim to significantly influence the landscape of clinical trials. They plan to implement a range of strategies designed to improve study designs, patient recruitment, and data collection processes—key areas in which both organizations excel.

P95 BV: A Leader in Clinical Trials

P95 is recognized globally for its specialization in vaccine development and epidemiology. The firm's comprehensive portfolio spans a multitude of crucial areas, including real-world evidence, ensuring impactful outcomes even in challenging environments. Their vast experiences contribute to the credibility and reliability of clinical trials conducted within the partnership.

LatinaBA: Regional Expertise

Established as a key regional CRO in Latin America, LatinaBA has developed a thorough understanding of local clinical trial requirements. The organization is proficient in managing complex clinical studies, including assays on Medical Devices, Observational Studies, and Real-World Evidence. Their extensive experience positions them as a vital player in advancing healthcare innovation in Latin America.

Future Implications for Healthcare in Latin America

The partnership between P95 and LatinaBA is poised to facilitate accelerated progress in vaccine research, overcoming barriers that have historically hampered clinical trials in the region. By enhancing local capacities and leveraging a collaborative framework, both firms are committed to a future where Latin America becomes a leader in vaccine development and infectious disease research.

In summary, this strategic partnership not only promises to uplift the clinical research framework in Latin America but also aims to contribute to the global fight against infectious diseases through innovation and cooperation.